[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"New York Medical College\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":516},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,41,69,91,112,139,162,190,210,235,257,280,305,329,350,368,386,411,434,461,487],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100640672","phase-1-cd30-car-t-cells-for-low-risk-relapsed-classical-hodgkin-lymphoma-100640672",false,"NCT07575893","CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma","REACH-CD30: Reinduction Therapy Followed by Engineered Autologous CD30.CAR T Cells in Children, Adolescents and Young Adults With Lower-Risk CD30+ Relapsed Classical Hodgkin Lymphoma NYMC 628","REACH-CD30","Inclusion Criteria:\n\n1. Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n2. Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo re-induction therapy.\n3. Confirmatory re-biopsy of relapsed CD30+ cHL prior to study entry.\n4. Risk Factors: Patient must meet established low-risk factors:\n\n   Stage at Diagnosis = IA, IIA\n   * 12 months from end of therapy OR 3-12 months from end of therapy with ≤3 cycles of treatment and no radiation NO B symptoms NO extra nodal disease at relapse NO relapse in a prior radiation field Stage at Diagnosis = IB, IIB, IIIA\n   * 12 months from end of therapy NO B symptoms NO extranodal disease at relapse NO relapse in a prior radiation field\n5. Female subjects of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 6 months after study treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n6. Male subjects with female partners must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 3 months after the cell infusion therapy.\n7. Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n8. Subject is willing and able to comply with study procedures based on the judgement of the investigator.\n9. Planned to undergo reinduction therapy and found to have a favorable response to one line of reinduction therapy. Patients who are refractory to initial reinduction attempts are considered high-risk and thus not eligible for Cell Product Administration and will be removed from study.\n\nExclusion:\n\n1. High-risk relapsed classical Hodgkin Lymphoma with any of the following:\n\n   B symptoms extra nodal disease at relapse relapse in a prior radiation field\n2. Patients under 6 years and over 29 years of age.","ALL","6 Years","29 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.",[28],"Classical Hodgkin Lymphoma","NOT_YET_RECRUITING","2026-05-18",{"date":32,"type":33},"2026-05-20","ACTUAL",{"date":35,"type":22},"2026-10-01",{"date":37,"type":22},"2032-12-01",{"name":39,"class":40},"New York Medical College","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100593986","phase-2-chemoimmunotherapy-for-alk-relapsedrefractory-alcl-100593986","NCT07013565","Chemoimmunotherapy for ALK+ Relapsed\u002FRefractory ALCL","NYMC623: A Comprehensive Risk-adapted Chemommunotherapy Protocol of Emerging Immunotherapies for Relapsed\u002FRefractory Alk+ Anaplastic Large Cell Lymphoma (ACCELERATE)","ACCELERATE","Inclusion Criteria:\n\n* Patients must weigh ≥10 kilograms at the time of study enrollment.\n* Patients with relapsed or refractory histologically or cytologically proven ALK-positive anaplastic large cell lymphoma meeting Low or High Risk Criteria:\n\nLow Risk Cohort (LR cohort):\n\n* Any patient with FIRST RELAPSE \\> ONE YEAR from initial diagnosis of de novo ALK+ ALCL,\n* Common histology,\n* CD3 negative, AND\n* No prior exposure to vinblastine (VBL).\n\nHigh-Risk Cohort (HR cohort):\n\n* Any patient with RELAPSED OR PROGRESSIVE DISEASE less than ONE YEAR from initial diagnosis of de novo ALK+ ALCL,\n* Small cell\u002Fhistiocytic histology,\n* CD3 positive (homogeneous staining of CD3 positive T-cells)\n* Patients must have adequate organ function.\n* Patients must have performance status 60 or above.\n\nExclusion Criteria:\n\n* ALK-NEGATIVE anaplastic large cell lymphoma.\n* Patients with active leptomeningeal disease (lymphoma cells in CSF).\n* Previous treatment with vinblastine (only in patients in the LR cohort).\n* Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarche.\n* Lactating females unless they have agreed not to breastfeed their infants.\n* Patients with Down syndrome.\n* Any patient with uncontrolled infection prior to study entry.\n* Any patient known to have primary or acquired immunodeficiency and\u002For prior solid organ transplant.","1 Year","39 Years",{"count":52,"type":22},20,[54],"PHASE2","Children, adolescents, and young adults (CAYA) with relapsed\u002Frefractory (R\u002FR) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overall survival. This clinical trial will investigate if a new FDA approved medication called Nivolumab (NIVO) (which is a checkpoint blockade immunotherapy) combined with chemotherapy based on the patients risk status to get the patient into the best response possible. Then patients will receive lower doses of chemoimmunotherapy and allogeneic stem cell transplantation (stem cells from another person). The investigators this this new treatment will improve survival rates in this high-risk population of patients.",[57],"Anaplastic Large Cell Lymphoma, ALK-Positive",[59,60],"ALCL","Relapsed ALCL","RECRUITING",{"date":32,"type":33},{"date":64,"type":33},"2025-08-07",{"date":66,"type":22},"2030-07-01",{"name":39,"class":40},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":68},"100563524","phase-1-cd30-car-t-cells-post-autohsct-for-poor-risk-hodgkin-lymphoma-100563524","NCT06617286","CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma","MAC-CAR: A Phase 1B\u002FII Trial of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Autologous CD30+ CAR T Cells in Children, Adolescents and Young Adults With Poor-Risk Classical Hodgkin Lymphoma (cHL)","Inclusion Criteria:\n\n* Age between ≥ 6 and ≤ 29.99 years at the time of consent.\n* Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)\n* Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following:\n\nInduction failure Progressive disease Disease relapse (1st, 2nd or 3rd)\n\n* Confirmatory re-biopsy of relapse\u002Frefractory\u002Fpersistent CD30+ cHL prior to study entry.\n* Risk Factors: Patient must meet 2 or more of the established risk factors:\n\nPerformance score (Karnofsky\u002FLansky) \\\u003C;90% Time from diagnosis to first relapse of \\\u003C1 year Extra nodal involvement at the time of relapse\u002Fprogression High baseline metabolic tumor volume (MTV, \\>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)\u002Fcomputed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction\n\nExclusion Criteria:\n\n* not meeting the inclusion criteria",{"count":5,"type":22},[25,54],"Patients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.",[28],[81,82],"classical Hodgkin lymphoma","CAR T-cells","2026-04-10",{"date":85,"type":33},"2026-04-15",{"date":87,"type":22},"2026-12-01",{"date":89,"type":22},"2040-12-31",{"name":39,"class":40},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":68},"100515101","phase-2-defibrotide-dose-escalation-for-sos-post-hsct-100515101","NCT05987124","Defibrotide Dose-escalation for SOS Post-HSCT","A Phase II Intrapatient Open-Label Dose Escalation Trial of Defibrotide in Hematopoietic Cell Transplantation (HCT) Recipients With Sinusoidal Obstructive Syndrome (SOS) Post-HCT Associated With Either Renal and\u002For Pulmonary Dysfunction With Either Refractory or Progressive Disease Following Defibrotide Therapy","Inclusion Criteria:\n\n* HCT recipients (Auto or Allograft)\n* SOS\u002FVOD as defined by Cairo\u002FCooke Diagnostic criteria (1) (Table 3) with either renal and\u002For pulmonary dysfunction as defined by Cairo\u002FCooke Grading criteria (1) (Appendix I).\n* Unresponsive to standard defibrotide therapy as defined by at least one of the following:\n* Patients with SOS\u002FVOD failing to obtain a complete response (CR) defined by Grade I or less by Cairo\u002FCooke Grading criteria (1) (Appendix I). This would therefore include patients with stable disease after at least 14 days of defibrotide or partial response after at least 21 days of defibrotide (25mg\u002Fkg\u002Fday).\n* Progressive disease defined by progression of at least one grade or more from diagnostic grade as defined by Cairo\u002FCooke Grading criteria (1) (Appendix I) following at least 7 days of defibrotide (25mg\u002Fkg\u002Fday).\n* Age 1 month - 75 years\n\nExclusion Criteria:\n\n* Patients who did not receive HCT.\n* Concomitant systemic anticoagulation (excluding central venous line management, fibrinolytic instillation for central venous line occlusion, management of intermittent dialysis or ultrafiltration of CVVH).\n* Active bleeding and\u002For hemorrhage of at least grade 2 and above.\n* History of development of Grade III\u002FIV anaphylaxis probably or directly secondary to defibrotide.\n* Female patients who are pregnant or breast feeding.","1 Month","75 Years",{"count":52,"type":22},[54],"This research study is being done to determine the safety and tolerability of increasing doses of defibrotide within a single patient with sinusoidal obstructive syndrome (SOS)\u002Fveno-occlusive disease (VOD) after hematopoietic cell transplantation (HCT) associated with either kidney and\u002For lung impairment that has not obtained a complete response (CR) or progressed in severity with standard doses of defibrotide.",[104,105],"Sinusoidal Obstruction Syndrome","Veno-occlusive Disease",{"date":85,"type":33},{"date":108,"type":33},"2024-03-20",{"date":110,"type":22},"2028-08-01",{"name":39,"class":40},{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":50,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":138},"100437182","phase-1-targeted-immunotherapy-after-myeloablative-tbi-based-conditioning--allohct-in-caya-with-high-risk-t-cell-all--lymphoma-100437182","NCT04972942","Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma","Phase I Trial of Targeted Immunotherapy With Daratumumab Following Myeloablative TBI-Based Conditioning and AlloHCT in Children, Adolescents and Young Adults With High Risk T-Cell Acute Lymphoblastic Leukemia and Lymphoma (ALLO-T-DART)","ALLO-T-DART","Inclusion Criteria:\n\n* 0-39yrs\n* T-cell ALL in second or subsequent remission (≤ 5% blasts) or relapsed T-cell LLy with complete response after re-induction therapy (including secondary malignancy)\n* Planned allogeneic stem cell transplantation with donor identified\n* Performance status ≥ 60%\n* Fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\n* Meet organ function requirements\n* Signed IRB approved informed consent\n\nExclusion Criteria:\n\n* May not have had a prior autologous or allogenic stem cell transplant\n* May not have uncontrolled, systemic infection at the time of enrollment\n* Known allergies, hypersensitivity, or intolerance to mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients\n* Must not be pregnant or actively breast feeding\n* Seropositive for HIV, hepatitis B or hepatitis C\n* COPD\n* Asthma\n* Clinically significant cardiac disease",{"count":121,"type":22},30,[25],"A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy).\n\nPre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.",[125,126],"T-cell Acute Lymphoblastic Leukemia","T-Cell Acute Lymphoblastic Lymphoma",[128,129,130,131],"immunotherapy","children","adolescents","young adults",{"date":85,"type":33},{"date":134,"type":33},"2023-05-22",{"date":136,"type":22},"2028-09",{"name":39,"class":40},16,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},"100431324","phase-1-sars-cov-2-ctls-for-mild-to-moderate-covid-19-disease-100431324","NCT04896606","SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease","A Pilot Study of SARS-CoV-2 Specific Cytotoxic T Lymphocytes (SARS-CoV-2-CTLs) for Treatment of Mild to Moderate Coronavirus Disease 2019 (COVID-19)","INCLUSION CRITERIA\n\n* Age ≥18 to 65 years. AND\n* Proven infection with SARS-CoV-2, defined as detection of SARS-CoV-2 by RT-PCR from nasopharyngeal swab or lower respiratory tract specimen AND\n* Hospitalized at the time of enrollment AND\n* HLA Matched Family Related donor with recent SARS-CoV-2 infection is at least 10 days out from symptom onset. A negative result for COVID-19 by a diagnostic test is not necessary to qualify the donor AND\n* In Stage I or II of disease (mild or moderate) at the time of enrollment (Table 1) AND\n* ONE of the following high-risk conditions:\n\n  * Chronic lung disease not requiring oxygen at home prior to admission (including but not limited to COPD, cystic fibrosis, asthma and sickle cell disease); Underlying heart disease (including hypertension); Patients with an acute myocardial infarction within the last 3 months will require cardiology clearance prior to enrollment; Diabetes mellitus (type I or II) ; Obesity (BMI ≥ 30); Immunosuppressed, based on investigator's assessment.\n\nEXCLUSION CRITERIA:\n\n* Stage III disease (severe) at the time of enrollment (see Table 1)\n* Lack of an identified eligible HLA family related donor\n* No high-risk comorbidities defined in the inclusion criteria (Section 5.1)\n* Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of enrollment\n* Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL Infusion\n* Patients with chronic respiratory failure requiring ventilator support and\u002For oxygen at home prior to admission are excluded\n* Patients with stage D heart failure and\u002For symptoms at rest are excluded\n* Renal function: patients with eGFR or CrCl \\\u003C30 mL\u002Fmin\u002F1.73 m2 will be excluded from study entry.\n* Liver function: Total bilirubin \\> 2 mg\u002Fdl (unless Gilbert's syndrome) OR ALT\u002FAST \\> 5 x ULN\n* Patients currently listed for transplant or potentially eligible to receive organ transplants are excluded from this study\n* Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤50%\n* Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment and for at least 6 weeks after the last dose of SARS-CoV-2 CTLS.\n* Male subjects with female partners of childbearing age who are not willing to use an effective method of birth control during study treatment and for at least 6 weeks after the last dose of SARS-CoV-2 CTLS.\n* Concurrent use of following medications is prohibited:\n\n  * Steroids (\\>2 mg\u002Fkg\u002Fday prednisone equivalent); Immunotherapies within 4 weeks prior to CTL infusion including checkpoint blockade, ATG, Campath, CAR T cells, blinatumomab; Chemotherapy: Tyrosine kinase inhibitors and hydroxyurea must be stopped \\> 72 hours prior to SARS-COV-2-CTL cell infusion; High dose chemotherapy must be stopped \\> 2 weeks prior to SARS-CoV-2-CTLs. High dose chemotherapy is defined in this protocol as any cancer directed therapy causing myelosuppression; Pegylated-asparaginase must be stopped \\> 4 weeks prior to SARS-COV-2-CTL infusion; Intrathecal chemotherapy must be stopped \\> 1 week prior to SARS-COV-2-CTL infusion (e.g. intrathecal methotrexate); Anti T-cell Antibodies: Administration of any T cell lytic or toxic antibody (e.g. alemtuzumab) within 30 days prior to SARS-CoV-2-CTLs is prohibited.","18 Years","65 Years",{"count":149,"type":22},50,[25,54],"The 2019 Severe Acute Respiratory Syndrome (SARS) is a global pandemic secondary to a novel coronavirus - SARS-CoV-2. The reported case-fatality ratio for SARS-CoV-2 in the United States is 1.8% with a current death toll of \\>300,000 and climbing.4 There is no accepted standard of care or FDA approved therapies for treatment of COVID-19. Virus specific cytotoxic T lymphocytes (CTLs) have become an important part of the treatment landscape for viral reactivation post hematopoietic and solid organ transplantation. Donor derived CTLs have been shown to be safe and effective against a variety of viruses including CMV, EBV, BK and adenovirus. We hypothesize that SARS-CoV-2 specific CTLs generated from a previously infected family donor will be safe and effective for treatment of COVID-19 in family members with mild to moderate disease.",[153],"Covid19",{"date":155,"type":33},"2026-04-13",{"date":157,"type":33},"2021-09-20",{"date":159,"type":22},"2026-12-31",{"name":39,"class":40},4,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":68},"100400218","phase-1-autologous-stem-cell-transplant-followed-by-polatuzumab-vedotin-in-patients-with-b-cell-non-hodgkin-and-hodgkin-lymphoma-100400218","NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma","Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma","Inclusion Criteria:\n\n* Diagnosis B-cell NHL: Burkitt lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Transformed Follicular Lymphoma, Richter syndrome, and CD20+ Hodgkin Lymphoma.\n* Disease Status Primary Induction Failure, 1st, 2nd or 3rd relapse\u002Fprogression having attained a CR, PR, or stable disease post reinduction therapy.\n* Performance Level Patients must have a performance status ≥ 50%. Use Karnofsky for patients \\> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.\n* Life Expectancy Patients must have a life expectancy of \\> 6 weeks.\n* Prior Therapy Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.\n\n  1. Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea).\n  2. Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent.\n* Organ Function Requirements\n\nAdequate Renal Function Defined As:\n\n* Creatinine clearance or radioisotope GFR \\> 60 mL\u002Fmin\u002F1.73 m2 or\n* A serum creatinine based on age\u002Fgender as follows:\n\nAge Maximum Serum Creatinine (mg\u002FdL) Male Female\n\n* 12 to \\\u003C 13 years 1.2 1.2 13 to \\\u003C 16 years 1.5 1.4\n* 16 years 1.7 1.4\n\n  * Adequate Liver Function Defined As:\n\n    * Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) for age, and\n    * SGOT (AST) or SGPT (ALT) \\\u003C 3 x upper limit of normal (ULN) for age for presumed hepatic leukemia or lymphoma.\n  * Adequate Cardiac Function Defined As:\n\n    * Shortening fraction of \\> 27% by echocardiogram, or\n    * Ejection fraction of \\> 50% by radionuclide angiogram.\n  * Adequate Pulmonary Function Defined As:\n\n    • Normal respiratory rate for age and a pulse oximetry \\> 94% on room air unless due to underlying malignancy.\n  * Peripheral Blood Stem Cell Collection\n\n    • Patients have a target of 5.0 x 106 CD34 (minimum of 2.5 x 106 CD34) PBSC collected and cryopreserved prior to start of myeloablative conditioning\n  * All patients and\u002For their parents or legal guardians must sign a written informed consent.\n\nExclusion Criteria:\n\n* Patient may not have had a prior stem cell transplant\n* Patients must not have active CNS lymphoma\n* Other concurrent investigational agents for treatment of B-cell lymphoma\n* Pregnancy and\u002For active Breast Feeding\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation.\n* Patient must not have an uncontrolled infection.\n* Patient must not have ≥ Grade 3 neuropathy.","12 Years","70 Years",{"count":52,"type":22},[25,54],"Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT). If patients achieve either complete, partial, or stable response following ASCT, they will receive an IV dose of Polatuzumab Vedotin once every 21 days until they receive 8 doses. After Polatuzumab Vedotin therapy is completed, patients will be followed every 4 months for about 2 years.",[175,176,177,178,179,180,181,182,183],"B-cell Lymphoma","Burkitt Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Transformed Non-Hodgkin Lymphoma","Richter Syndrome","Hodgkin Lymphoma",{"date":85,"type":33},{"date":186,"type":33},"2021-08-01",{"date":188,"type":22},"2027-08-15",{"name":39,"class":40},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":68},"100387362","phase-1-dose-dense-rituximab-for-high-risk-newly-diagnosed-acute-immune-thrombocytopenic-purpura-100387362","NCT04323748","Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura","The Use of Dose Dense Rituximab for High Risk Patients With Newly Diagnosed Acute Immune Thrombocytopenic Purpura","NYMC207","Inclusion Criteria:\n\n* Age: Subjects must be ≥ 1 year and ≤ 21 years of age.\n* Diagnosis: Patients must have newly diagnosed ITP and a platelet count of ≤ 20 x 109 per Liter. Bone marrow aspirate and biopsy should be performed to rule out malignancy in the bone marrow.\n* High-risk features : In addition, patients must have one of more of the following high-risk criteria:\n\n  * Age ≥ 10 years\n  * Grade II-IV bleeding at diagnosis\n  * ANA positivity\n  * No history of preceding infection within 2 weeks prior to ITP diagnosis\n* Performance Status: Patients must have a performance status ≥ 50%. Use Karnofsky for patients \\> 16 years of age and Lansky for patients less than or equal to 16 years of age. See Appendix I for performance score.\n* Prior Therapy\n\n  * Patients may not have received any treatment for ITP prior to start of therapy.\n  * Patients may not receive systemic steroids ≥ 0.5 mg\u002Fkg prednisone (or equivalent) within 2 weeks prior to diagnosis.\n* Concomitant Medications Restrictions:\n\n  * Steroids are only warranted as premedication prior to rituximab.\n  * Patients who receive thrombopoetic agonists, eltrombopag or romiplostim will be taken off protocol.\n* Organ Function Requirements\n\n  * Adequate Renal Function Defined As: estimated CrCl \\> 60 mL\u002Fmin or \\>30% of GFR for age based on the Schwartz formula\n  * Adequate Liver Function Defined As: AST and\u002For ALT less than 5 times the upper limit of normal, and\u002For direct bilirubin less than the 2 times of the upper limit of normal\n\nExclusion Criteria\n\n* Patients with a history of Grade III-IV allergic reaction to rituximab\n* Patients with bone marrow neoplastic infiltration\n* Patients with a history of hepatitis B infection\n* Pregnancy and Breast Feeding\n\n  * Female patients who are pregnant are ineligible (insert the reason: \"due to risks of fetal and teratogenic adverse events as seen in animal\u002Fhuman studies\" or \"since there is yet no available information regarding human fetal or teratogenic toxicities\").\n  * Lactating females are not eligible unless they have agreed not to breastfeed their infants.\n  * Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.","21 Years",{"count":52,"type":22},[25],"The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment.\n\nCorrelative studies will be performed as outlined in the appendices.\n\nQuality of Life will be measured using the KIT as outlined in the protocol.",[203],"Immune Thrombocytopenic Purpura",{"date":85,"type":33},{"date":206,"type":33},"2021-02-24",{"date":208,"type":22},"2027-07-31",{"name":39,"class":40},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":220,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":68},"100386177","phase-1-vorinostat-in-combination-with-chemotherapy-in-relapsedrefractory-solid-tumors-and-cns-malignancies-100386177","NCT04308330","Vorinostat in Combination With Chemotherapy in Relapsed\u002FRefractory Solid Tumors and CNS Malignancies","A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies","NYMC195","Inclusion Criteria:\n\n* Age: Patients must be less than or equal to 1 year and less than or equal to 30 years of age at initiation of protocol therapy.\n* Diagnosis: Patients must have a confirmed histologic diagnosis of a relapsed or refractory solid tumor or CNS malignancy.\n* Performance status: Patients over 16 years of age must have a Karnofsky score greater than or equal to 50. Children under 16 years of age must have a Lansky score greater than or equal to 50.\n* Prior therapy: Patients may have received prior therapy with vincristine, irinotecan, or temozolomide. They may not however have received therapy that included a treatment cassette of irinotecan and temozolomide in combination.\n\n  * Prior myelosuppressive therapy: Patients must have not received myelosuppressive therapy in 3 weeks or nitrosourea chemotherapy within 6 weeks of initiation of protocol therapy.\n  * Hematologic growth factor support: Patients may not have received G-CSF within the previous 3 days or peg-filgrastim within the past 7 days.\n  * Biologic anti-neoplastic therapy: At least 21 days or 5 half-lives (whichever is of longer duration) must have elapsed since the last administration of biologic antineoplastic therapy.\n  * Radiation therapy: ≥ 14 days since the last dose of local XRT; ≥ 6 months must have elapsed if prior TBI, craniospinal XRT or ≥ 50% radiation of pelvis; ≥ 6 wks must have elapsed if other substantial BM radiation.\n  * Autologous or allogeneic stem cell transplant: No active graft vs. host disease or need for immunosuppressive therapy. At least 3 months must have passed since neutrophil engraftment.\n* Organ function:\n\nBone marrow function:\n\n* Peripheral absolute neutrophil count (ANC) greater than or equal to 1000 cells\u002FmcL.\n* Platelet count greater than or equal to100,000\u002FmcL and no platelet transfusion within prior 7 days.\n* Hemoglobin greater than or equal to 8 gm\u002FdL\n* Patients with known bone marrow metastatic disease may enroll on the study if they have a peripheral ANC greater than or equal to 750 cells\u002FmcL. They will not be evaluable for hematologic toxicity.\n\n  \\- Adequate liver function:\n* Total bilirubin less than or equal to 1.5x upper limit of normal (ULN) for age.\n* SGPT (ALT) less than or equal to 5x ULN\n* Serum albumin greater than or equal to 2 gm\u002FdL\n\n  \\- Adequate renal function:\n* Creatinine clearance or glomerular filtration rate \\>70 ml\u002Fmin\u002F1.73 m2 or a serum creatinine based on age and gender as follows:\n\nAge Maximum serum creatinine concentration (mg\u002FdL) Male Female 1-\\\u003C2 years 0.6 0.6 2-\\\u003C6 years 0.8 0.8 6-\\\u003C10 years 1 1 10-\\\u003C13 years 1.2 1.2 13-\\\u003C16 years 1.5 1.4 greater than or equal to 16 years 1.7 1.4 The threshold creatinine values in this table were derived from the Schwartz formula to estimate glomerular filtration rates (Schwartz et al. J. Peds. 106; 522. 1985) using child length and stature data from the CDC.\n\n\\- Informed consent: All patients less than 18 years of age must sign a written informed consent. For patients \\\u003C18 years of age, a parent or guardian must sign a written informed consent, unless the patient is an emancipated minor. Childhood assent, when appropriate, should be obtained as well per institutional guidelines.\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding: Women who are pregnant or breast feeding will not be entered on the protocol due to the risks of fetal and teratogenic adverse events with the therapeutic agents used in the protocol therapy.\n* Corticosteroid use: Patients with CNS tumors who have not been on a stable or decreasing dose of corticosteroids for the 7 days prior to the initiation of protocol therapy.\n* Antineoplastic therapy: Patients receiving any other antineoplastic therapy.\n* Medication allergy:\n\nAllergy or intolerance to any of the protocol agents: vincristine, irinotecan, temozolomide, or vorinostat.\n\nAllergy or intolerance to cephalosporins.\n\n* Infection: Patients who have any uncontrolled infection, positive blood culture within 48 hours prior to protocol entry, or diagnosed or receiving therapy for Clostridium difficile infection.\n* Patients may not have taken valproic acid or any other histone deacetylase inhibitor for at least 2 weeks prior to study enrollment.\n* Children with neurofibromastosis Type 1, if being used for treatment of a low grade glioma.","30 Years",{"count":121,"type":22},[25],"Investigators are testing new experimental drug combinations such as the combination of vorinostat, vincristine, irinotecan, and temozolomide in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy.\n\nThe goals of this study are:\n\n* To find the highest safe dose of vorinostat that can be given together with vincristine, irinotecan, and temozolomide without causing severe side effects;\n* To learn what kind of side effects this four drug combination can cause;\n* To learn about the effects of vorinostat and the combination of vorinostat, vincristine, irinotecan, and temozolomide on specific molecules in tumor cells;\n* To determine whether the combination of vorinosat, vincristine, irinotecan, and temozolomide is a beneficial treatment.",[223,224,225,226,227,228],"Ewing Sarcoma","Rhabdomyosarcoma","Wilms Tumor","Neuroblastoma","Hepatoblastoma","Germ Cell Tumor",{"date":85,"type":33},{"date":231,"type":33},"2017-03-17",{"date":233,"type":22},"2027-12-31",{"name":39,"class":40},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":242,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},"100377674","phase-1-treatment-of-refractory-bk-infections-with-related-donor-bk-specific-cytotoxic-t-cells-ctls-100377674","NCT04197596","Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)","A Pilot Study in the Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients","Inclusion Criteria:\n\n.1.1 Patients with refractory BK infection post allogeneic HSCT, post solid organ transplantation or with primary immunodeficiencies with either\n\n* Increasing urine and\u002For plasma BK RT-PCR DNA (by 1 log) after 7 days or persistent quantitative qRT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n\n  * 2 renal toxicity with cidofovir or other \\> grade 2 toxicities secondary to cidofovir And\u002For\n* known resistance to cidofovir 1.2. Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\n1.3 Performance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) 1.4 Age: 0.1 to 79.99 years 1.5 Females of childbearing potential with a negative urine pregnancy test\n\nExclusion:\n\n1. Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of BK CTL infusion\n2. Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of BK CTL infusion\n3. Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to BK CTL infusion\n4. Thymoglobulin (ATG) or Alemtuzumab within 30 days\n5. Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30%\n6. Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK infection.\n7. Any medical condition which could compromise participation in the study according to the investigator's assessment\n8. Known HIV infection\n9. Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n10. Known hypersensitivity to iron dextran\n11. Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n12. Known human anti-mouse antibodies","79 Years",{"count":244,"type":22},40,[25,54],"BK cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be safe and effective in decreasing specific viral load in children, adolescents and young adults (CAYA) with refractory BK infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) or with primary immunodeficiencies (PID).",[248,249],"Viral Infection","Primary Immune Deficiency Disorder",{"date":85,"type":33},{"date":252,"type":33},"2020-07-01",{"date":254,"type":22},"2027-06-30",{"name":39,"class":40},7,{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":161},"100482635","phase-2-cmv-ctls-in-neonates-with-cmv-infection-100482635","NCT05564598","CMV CTLs in Neonates With CMV Infection","A Phase II Open-Label Randomized Study of Anti-Viral Antibiotic Therapy With and Without Familial (Maternal) Cytomegalovirus (CMV) Cytotoxic T Lymphocytes (CTLs) in Neonates With Moderate\u002FSevere Maternal Acquired CMV Infection","Inclusion Criteria:\n\n* Age: ≤ 21 days of life\n* Birth Weight: ≥ 2500 gms\n* Gestational age: ≥ 34 weeks of age\n* Diagnosis of CMV viremia, viruria, and\u002For infection:Either one or more:\n\nElevated CMV by RT-PCR in urine, saliva, CSF, or plasma; and\u002For Positive urine culture for CMV\n\n\\- Moderate or Severe CMV Disease\n\nAny one or more of the following attributable to congenital CMV infection:\n\n* Thrombocytopenia (≤ 50,000 mm3)\n* Multiple petechiae\n* Hepatomegaly\n* Splenomegaly\n* Intrauterine growth retardation\n* Increased transaminases\n* Increased bilirubin\n* Microcephaly\n* Ventriculomegaly\n* Intracerebral calcifications\n* Periventricular echogenicity\n* Cortical or cerebral malformation\n* Chorioretinitis\n* Severe neonatal hearing loss\n* CMV DNA by PCR in CNS\n* Increased WBC for age in CNS\n\n  * Minimal Organ Criteria Hematological: ANC ≥ 750\u002Fmm3, HgB ≥ 8gm\u002Fdl, Platelets ≥ 20,000\u002Fkmm3 Renal: Serum creatinine ≤ 1.0 mg\u002Fdl Hepatic: ALT\u002FSGOT ≤3x upper normal limits\n  * Donor Availability: Maternal donor available with a T-cell response CMV MACS® PepTivators. the donor is considered suitable if the percentage of IFN-gamma+ T cells is \\> 0.01% after stimulation with PepTivators.\n\nExclusion Criteria -\n\n* Patient receiving steroids (\\> 0.5 mg\u002Fkg prednisone equivalent) on the same day of CMV CTL infusion. Antenatal steroids for lung maturation will have been cleared prior to CMV diagnosis.\n* Concomitant enrollment in another experimental clinical trial investigating the treatment of neonatal CMV viremia and\u002For infection.\n* Any medical condition that could compromise participation in the study according to the investigator's assessment.\n* Known history of HIV infection in the mother.\n* Patient's legally authorized representative unwilling or unable to comply with the protocol or unable to give informed consent.","0 Days","21 Days",{"count":267,"type":22},23,[54],"Patients with moderate or severe CMV disease less than 21 days old who have a maternal donor who has a CMV response to the peptivators will be screened.\n\nAll patients will receive treatment with valganciclovir or ganciclovir. There is a safety run in with treatment with CMV CTLs in cohort 1 and if found to be safe, will proceed to cohort 2 for randomization to receive antiviral therapy with or without CMV CTLs.\n\nFunding source: FDA OOPD",[271],"Congenital Cytomegaloviral (CMV) Disease","2026-03-24",{"date":274,"type":33},"2026-03-30",{"date":276,"type":33},"2023-07-01",{"date":278,"type":22},"2028-10-31",{"name":39,"class":40},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":218,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":304,"locationsCount":4},"100610314","phase-3-phase-3-randomized-trial-for-refractory-adv-or-cmv-infection-with-family-matched-ctls-and-standard-of-care-soc-vs-soc-alone-100610314","NCT07225972","Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC Alone","An Open-Label Prospective Randomized Trial of Family Donor-Derived ADV or CMV CTLs Plus Standard of Care (SOC) vs SOC Alone in Children, Adolescents and Young Adults Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) With Refractory ADV or CMV Infection\u002FViremia","Patient Eligibility Cohort 1 (ADV) -Patients with ADV infections (Cohort 1) (pneumonitis, hepatitis, cystitis, and\u002For colitis) post AlloHSCT with one or more of the following: Increasing or persistent ADV RT-PCR DNA (\\> 1000 ADV PCR copies) after 7 days of appropriate anti-viral therapy AND\u002FOR Medical intolerance to anti-viral therapies including one or more of the following: \\> grade 2 renal insufficiency secondary to cidofovir and\u002For other \\> grade 2 toxicities secondary to cidofovir AND\u002FOR Known resistance to cidofovir\n\nPatient Eligibility (Cohort 2) (CMV)\n\n-Patients with CMV infections (pneumonitis, hepatitis, colitis) with one or more of the following: Increasing or persistent CMV RT-PCR DNA (\\>1000 copies) after 7 days of appropriate anti-viral therapy AND\u002FOR Medical intolerance to anti-CMV antibiotic therapies: ANC \\> 500\u002Fmm3 secondary to ganciclovir AND\u002FOR \\> grade 2 renal toxicity secondary to either foscarnet or cidofovir AND\u002FOR Known resistance to ganciclovir and\u002For foscarnet\n\n* Consent: written informed consent given (by patient or legal representative) prior to any study related procedures\n* Performance Status \\>30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 years (BOTH COHORTS)\n* Age: 0.01 to 30.00 years (BOTH COHORTS)\n* Females of childbearing potential with a negative urine pregnancy test at study entry only (BOTH COHORTS)\n\nDonor Eligibility\n\n* Related donor available with a T-cell response to the ADV MACS PepTivators (Cohort 1) or CMV MACS PepTivator (Cohort 2). As defined in Appendix II, B, 8.2, the donor is considered suitable if the percentage of IFN+ T-cells is \\>0.01% after stimulation with ADV PepTivators (Cohort 1) or CMV PepTivators (Cohort 2).\n* Third-party related allogeneic donor: If original donor is not available or does not have a T-cell response to ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2), third party allogeneic donor (family donor \\> 3 HLA A, B, DR match to recipient) with a T-cell response at least to the ADV MCAS PepTivator (Cohort 1) or CMV PepTivator (Cohort 2) AND\n* Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1) AND\n* Obtained informed consents by donor or donor legally authorized representative prior to donor collection\n\nPatient Exclusion Criteria (Both Cohorts)\n\n* Patient with acute GVHD \\> grade 2 or moderate or extensive chronic GVHD at the time of CTL infusion.\n* Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CTL infusion.\n* Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion.\n* Patient with poor performance status determined by Karnofksy (patients \\> 16 yrs) or Lansky (patients \\\u003C 16 years) score \\\u003C 30%.\n* Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory ADV or CMV infections.\n* Any known medical condition which cold compromise participation in the study according to investigators assessment.\n* Known AIDS or uncontrolled HIV infection\n* Known hypersensitivity to iron dextran\n* Encephalitis and\u002For retinitis","1 Day",{"count":289,"type":22},69,[291],"PHASE3","Patients with refractory ADV or CMV infection post allogeneic stem cell transplant will be randomized to either Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone.",[294,295,296,297,298],"CMV","AdV Infection","AdV Reactivation","Adenovirus","Cytomegalovirus Infections","2025-11-06",{"date":301,"type":33},"2025-11-10",{"date":87,"type":22},{"date":37,"type":22},{"name":39,"class":40},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":314,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":328},"100340943","early-phase-1-chemoimmunotherapy-and-allogeneic-stem-cell-transplant-for-nk-t-cell-leukemialymphoma-100340943","NCT03719105","Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia\u002FLymphoma","Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lymphoma\u002FLeukemia in Children, Adolescents and Young Adults; A NK\u002FT-Cell Lymphoma\u002FLeukemia Consortium Study","Inclusion Criteria:\n\n* Patients must weigh at least 10 kilograms at the time of the study enrollment.\n* Diagnosis\n\nNewly diagnosed patients with histologically proven mature T- and NK- cell neoplasms:\n\nCOHORT 1\n\n* Aggressive NK cell leukemia (ICD-O code 9948\u002F3)\n* Extranodal NK\u002FT-cell lymphoma, nasal type (ICD-O code 9719\u002F3) COHORT 2\n* Enteropathy-associated T-cell lymphoma (ICD-O code 9717\u002F3)\n* Hepatosplenic T-cell lymphoma (ICD-O code 9716\u002F3)\n* Peripheral T-cell lymphoma, non-otherwise specified (ICD-O code 9702\u002F3)\n* Angioimmunoblastic T-cell lymphoma (ICD-O code 9705\u002F3)\n* Other mature T- and NK-cell neoplasm histologies will considered after case-by-case discussion with Study Chairs and executive Vice-Chair Patients with lymphoma must have stage III or IV disease (See Appendix III for Staging).\n\n  * Organ Function Requirements\n\nAdequate liver function defined as:\n\n* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age.\n* ALT (SGPT) \\\u003C 3 x ULN for age.\n\nAdequate cardiac function defined as:\n\n* Shortening fraction of ≥ 27% by echocardiogram, or\n* Ejection fraction of ≥ 50% by radionuclide angiogram.\n\nAdequate pulmonary function defined as:\n\n• Patients with a history of pulmonary dysfunction must have no evidence of dyspnea at rest, no exercise intolerance due to pulmonary insufficiency, and a pulse oximetry \\> 92% while breathing room air unless current dysfunction is due to the lymphoma, in which case the patient is eligible.\n\nExclusion Criteria:\n\n* Alk+ or Alk- Anaplastic Large Cell Lymphoma (ALCL)\n* Patients with active CNS disease.\n* Patients with stage I or stage II disease (See Appendix III for Staging).\n* Patients who have received any prior cytotoxic chemotherapy for the current diagnosis of NHL.\n* Previous steroid treatment and\u002For radiation treatment are not allowed unless they are used for emergency management. Patients who have received emergency irradiation and\u002For steroid therapy will be eligible only if started on protocol therapy not more than one week from the start of radiotherapy or steroids.\n* Female patients who are pregnant. Pregnancy tests must be obtained in girls who are post menarchal.\n* Lactating females, unless they have agreed not to breastfeed their infants.\n* Patients with Down syndrome.\n* Patients taking CYP3A4 substrates with narrow therapeutic indices. Patients (COHORT 2 ONLY) chronically receiving medications known to be metabolized by CYP3A4 and with narrow therapeutic indices (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inhibitors. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inhibitors within 7 days prior to study enrollment (See Appendix V). The topical use of these medications (if applicable) is allowed.\n* Patients taking CYP3A4 inducers. Patients (COHORT 2 ONLY) chronically receiving drugs that are known potent CYP3A4 inducers within 12 days prior to study enrollment (See Appendix V).","31 Years",{"count":244,"type":22},[315],"EARLY_PHASE1","Patients are in 2 cohorts:\n\nCohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma\u002Fleukemia) .\n\nBoth groups proceed to allogeneic stem cell transplant with disease response.",[318,319,320],"NK-Cell Lymphoma","NK-Cell Leukemia","Peripheral T Cell Lymphoma",{"date":322,"type":33},"2025-08-08",{"date":324,"type":33},"2019-03-01",{"date":326,"type":22},"2028-12-31",{"name":39,"class":40},6,{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":242,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":340,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":349},"100306238","phase-2-adenovirus-specific-cytotoxic-t-lymphocytes-for-refractory-adenovirus-infection-100306238","NCT03266627","Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection","A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients","1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:\n\n   * Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and\u002For\n   * clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND\u002FOR\n   * Medical intolerance to anti-viral therapies including:\n\n     * grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\n   Performance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79 years\n\n   Females of childbearing potential with a negative urine pregnancy test\n2. Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus.\n\n   a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus.\n\n   AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\n   AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n3. Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\n. Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies\n\n\\-",{"count":52,"type":22},[54],"Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[297,249],[341,342,343],"adenovirus","primary immune deficiency disorder","cytotoxic t-lymphocytes",{"date":322,"type":33},{"date":346,"type":33},"2018-11-01",{"date":233,"type":22},{"name":39,"class":40},10,{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":242,"enrollmentInfo":357,"targetDuration":4,"studyType":23,"phases":358,"briefSummary":359,"conditions":360,"keywords":361,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":363,"startDateStruct":364,"completionDateStruct":365,"leadSponsor":366,"locationsCount":367},"100306239","phase-2-virus-specific-cytotoxic-t-lymphocytes-ctls-for-refractory-cytomegalovirus-cmv-100306239","NCT03266640","Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)","A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients","1\\. Patients with refractory CMV infection post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with either\n\n* Increasing or persistent quantitative qRT-PCR DNA copies despite two weeks of appropriate anti-viral therapy AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n* ANC \\\u003C 500\u002Fmm2 secondary to ganciclovir\n\n  * 2 renal toxicity with foscarnet And\u002For\n* known resistance to ganciclovir and\u002For foscarnet\n\nConsent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\nPerformance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79.99 years Females of childbearing potential with a negative urine pregnancy test\n\nDonor Eligibility Related donor available with a T-cell response to the CMV MACS® GMP PepTivator antigen(s).\n\na. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party related allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with IgG positive to CMV and\u002For a T-cell response to the CMV MACS® GMP PepTivator .\n\nAND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\nAND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n\n3 Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\nPatient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CMV CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CMV CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CMV CTL infusion Thymoglobulin (ATG), Alemtuzumab or T cell immunosuppressive monoclonal antibodies within 30 days Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% CMV retinitis Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory CMV infection.\n\nAny medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies CMV retinitis, meningitis, encephalitis, and\u002For cerebritis",{"count":52,"type":22},[54],"CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[298,249],[362,294,343],"Cytomegalovirus",{"date":322,"type":33},{"date":346,"type":33},{"date":233,"type":22},{"name":39,"class":40},9,{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":17,"minAge":98,"maxAge":242,"enrollmentInfo":375,"targetDuration":4,"studyType":23,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":385},"100306240","phase-2-ebv-specific-cytotoxic-t-lymphocytes-ctls-for-refractory-ebv-infection-100306240","NCT03266653","EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection","A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients","1\\. Patients with Epstein-Barr virus infections post allogeneic HSCT, primary immunodeficiencies or post solid organ transplant with:\n\n* Increasing or persistent quantitative EBV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and\u002For\n* progressive clinical symptoms attributable to EBV, including biopsy proven colitis, lymphadenopathy, hepatomegaly, splenomegaly AND\u002FOR\n* Medical intolerance to anti-viral therapies including:\n* intolerance to rituximab Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n\nPerformance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs) Age: 0.1 to 79.99 years Females of childbearing potential with a negative urine pregnancy test\n\n2 Donor Eligibility 5.2.1 Related donor available with a T-cell response to the EBV MACS® GMP PepTivator antigen(s) causing the therapy-refractory EBV infection.\n\na. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party related allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with IgG positive to EBV and\u002For a T-cell response at least to the viral MACS® GMP PepTivator EBV Select (containing among other antigens, NA-1, LMP2A and BZLF-1).\n\nAND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\nAND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n\n3 Patient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\nPatient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory EBV infection Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n\nKnown hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n\nKnown human anti-mouse antibodies",{"count":52,"type":22},[54],"Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.\n\nFunding Source: FDA OOPD",[379,249],"Epstein-Barr Virus Infections",{"date":322,"type":33},{"date":382,"type":33},"2020-07-07",{"date":233,"type":22},{"name":39,"class":40},8,{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":17,"minAge":394,"maxAge":312,"enrollmentInfo":395,"targetDuration":4,"studyType":23,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":68},"100239288","phase-2-obinutuzumab-and-ice-chemotherapy-in-refractoryrecurrent-cd20-mature-nhl-100239288","NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL","Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL","O-ICE","Inclusion Criteria:\n\n* Patients in first relapse or primary induction failure CD20 positive B-cell leukemia\u002Flymphoma including:\n\n  * Diffuse Large B-Cell Lymphoma\n  * Burkitt Lymphoma\n  * High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)\n  * Primary mediastinal B-cell lymphoma (PMBL)\n  * CD20+ B-lymphoblastic lymphoma\n  * Follicular lymphoma, Grade III\n  * Karnofsky ≥ 60% for patients \\> 16 years of age and\n  * Lansky ≥ 60 for patients ≤ 16 years of age.\n  * Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.\n  * Patients may not have received prior therapy with obinutuzumab (GA101)\n  * Radiation Therapy (XRT): Date of receiving prior XRT must be \\> 2 weeks for local palliative XRT (small port); \\> 6 months must have elapsed if prior craniospinal XRT or if \\> 50% radiation of pelvis; \\> 6 weeks must have elapsed if other substantial bone marrow radiation.\n  * Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.\n  * Adequate organ function.\n\nExclusion Criteria:\n\n* Patients with newly diagnosed, previously untreated B-NHL.\n* Known congenital or acquired immune deficiency.\n* Prior solid organ transplantation.\n* Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.\n* History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies\n* Uncontrolled hepatitis B and\u002For C infection","3 Years",{"count":396,"type":22},25,[54],"The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).",[400,176,401,402,403,404],"Non-Hodgkin Lymphoma","Diffuse Large B-Cell Lymphoma","Primary Mediastinal B-cell Lymphoma","CD20+ Lymphoblastic Lymphoma","Follicular Lymphoma, Grade III",{"date":322,"type":33},{"date":407,"type":33},"2015-08-21",{"date":409,"type":22},"2027-12",{"name":39,"class":40},{"id":412,"slug":413,"hasResults":11,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":11,"sex":17,"minAge":394,"maxAge":50,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":433},"100458736","phase-2-chemoradiotherapy-with-targeted-immunotherapy-in-pediatric-lymphoma-100458736","NCT05253495","Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","Reducing the Burden of Oncologic Chemoradiotherapy And Radiation Exposure From Diagnostic Imaging by Utilizing Targeted Immunotherapy in Children, Adolescents and Young Adults With Lymphoma","RADICAL","Inclusion Criteria:\n\n* Newly diagnosed patients with histologically or cytologically proven newly diagnosed MB-NHL or cHL according to WHO Classification who meet the following criteria are eligible:\n\nCOHORT I:\n\nBurkitt lymphoma (ICD-O 9687\u002F3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687\u002F3) Diffuse large B-cell lymphoma, NOS (ICD-O 9680\u002F3) High grade B-cell lymphoma (ICD-O 9680\u002F3)\n\nCOHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) (GROUP B)61\n\nCOHORT Ib: any CNS involvement and\u002For BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR patients with less than 20% tumor size reduction post chemotherapy with cyclophosphamide, dexamethasone, vincristine (DOC Reduction for Cohort Ia).\n\nCOHORT II Classical Hodgkin lymphoma (ICD-O 9650\u002F3, 9663\u002F3, 9651\u002F3, 9652\u002F3, 9653\u002F3)\n\nCOHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)\n\nCOHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)\n\n* Adequate organ function\n\nExclusion Criteria:\n\n* Primary mediastinal B-cell lymphoma (PMBL)\n* T-cell\u002Fhistiocyte-rich large B-cell lymphoma\n* Gray zone lymphoma\n* Follicular lymphoma\n* Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)\n* Posttransplant lymphoproliferative lymphoma (PTLD)",{"count":420,"type":22},80,[54],"The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).",[424,183],"Non-hodgkin Lymphoma","2025-06-10",{"date":427,"type":33},"2025-06-13",{"date":429,"type":33},"2022-02-01",{"date":431,"type":22},"2028-06-30",{"name":39,"class":40},3,{"id":435,"slug":436,"hasResults":11,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":441,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":68},"100592944","combined-aphasia-and-robot-assisted-arm-treatment-for-chronic-stroke-survivors-100592944","NCT07000019","Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors","CARAT","Inclusion Criteria:\n\n1. Male or female patients between 18-90 years of age.\n2. Right-handed prior to stroke\n3. English-speaking (monolingual)\n4. History of single left-hemisphere stroke at least 6 months prior to enrollment\n5. Presence of aphasia and naming deficits on Western Aphasia Battery (WAB-R)\n6. Comprehension score above 4 on WAB-R\n7. Unilateral upper limb paresis (Fugl-Meyer Upper Extremity score \\\u003C56)\n8. Documentation of signed Informed Consent by the study participant.\n\nExclusion Criteria:\n\n1. Diagnosis or history of speech impairment prior to stroke\n2. Severely limited speech output (score below 2 on spontaneous speech portion of WAB-R)\n3. Inability to perform screening tasks due to severe language and\u002For cognitive impairment\n4. Condition limiting passive movement in the range of motion required for robotic therapy (e.g. fixed contracture)\n5. Any medical or psychiatric condition that may impact participation or compliance with study procedures or activities in the opinion of the investigator","90 Years",{"count":443,"type":22},28,[445],"NA","The goal of this clinical trial is to learn if a program that combines language and arm treatment can improve language and movement problems in people with chronic stroke. The mains questions it aims to answer are:\n\n* To determine the extent to which this combined treatment can improve language.\n* To determine the extent to which the combined treatment can improve arm movements.\n\nResearchers will compare the effects of this combined treatment with treatment that targets arm movements alone.",[448,449,450],"Stroke","Aphasia Following Cerebral Infarction","Hemiparesis After Stroke",[452],"stroke, aphasia, hemiparesis, robotic","2025-05-23",{"date":455,"type":33},"2025-05-31",{"date":457,"type":22},"2025-06",{"date":459,"type":22},"2027-11",{"name":39,"class":40},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":17,"minAge":469,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":472,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":161},"100260933","phase-2-myeloablative-conditioning-prophylactic-defibrotide-and-haplo-allosct-for-patients-with-sickle-cell-disease-100260933","NCT02675959","Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease","Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback","NYMC-571","Inclusion Criteria:\n\n* Disease: Homozygous Hemoglobin S Disease, or Hemoglobin S B0\u002F+ thalassemia, or Hemoglobin SC Disease, or Beta thalassemia intermedia\u002Fmajora\n* Patients must demonstrate one or more of the following Sickle Cell Disease Complications (or patients in Cohort 2 can meet other high risk criteria instead)\n* Clinically significant neurologic event (stroke) or any neurologic deficit lasting \\>24 hours that is accompanied by an infarct on cerebral MRI\n* Acute chest syndrome in the preceding two year period prior to enrollment that have failed, been non-compliant or declined hydroxyurea treatment, or prior to chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis.\n* Recurrent painful events (at least 3 in the 2 years prior to enrollment or prior to chronic chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis).\n* Abnormal TCD study requiring starting on chronic transfusion therapy and\u002For exchange transfusions.\n* At least one silent infarct lesion on a MRI scan of the head. Or (directly or probably related to SCD)\n* Sickle Cell nephropathy;\n* Splenic sequestration requiring RBC transfusion;\n* Aplastic crisis requiring RBC transfusion;\n* Avascular necrosis of the hip diagnosed by MRI;\n* Two episodes or more of leg ulcerations;\n* Recurrent priapism .\n* Infant dactylitis.\n\n  * OR for Cohort #2 ONLY: Patient must be between 18 and 34.99 years of age, patients must demonstrate at least two of the following:\n* WBC \\> 13,500 cells\u002Fmicroliter at baseline when not acutely ill (on two separate occasions) \\> 2 weeks from a VOC event or hospitalization.\n* Tricuspid Regurgitant Jet Velocity (TRV) \\> 3.0 m\u002Fs\n* Requiring Chronic Monthly Transfusions ( \\> 12 transfusions in the 12 months)\n* History of sepsis\n* N-terminal pro-brain natriuretic peptide (NT-proBNP) \\> 160 ng\u002FL at clinical baseline when not acutely ill or hospitalized.\n* all patients must meet disease, age, organ function and donor criteria;\n\nExclusion Criteria:\n\n* Patients who are receiving concomitant systemic anticoagulants and\u002For fibrinolytic therapies.\n* Patients with a previously known hypersensitivity reaction to defibrotide.\n* Females who are pregnant or breast-feeding are not eligible\n* SCD Patients with documented uncontrolled infection at the time of study entry are not eligible.\n* SCD patients who have an unaffected HLA matched family donor willing to proceed to donation will not be eligible for this study.\n* Karnofsky or Lansky (age appropriate) Performance Score \\\u003C50% (hemiplegia alone secondary to a previous stroke is not an exclusion)\n* Demonstrated lack of compliance with medical care.\n* Patients with clinically significant fibrosis or cirrhosis of the liver will not be eligible.\n* Patients who have previously received a HSCT will not be eligible.\n* Patients with contraindications to the use of defibrotide","6 Months","34 Years",{"count":244,"type":22},[54],"This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD.",[475],"Sickle Cell Disease",[477,478,479,480],"stem cell transplantation","sickle cell disease","haploidentical","defibrotide","2025-05-20",{"date":453,"type":33},{"date":484,"type":33},"2017-07-01",{"date":409,"type":22},{"name":39,"class":40},{"id":488,"slug":489,"hasResults":11,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":492,"eligibilityCriteria":493,"healthyVolunteers":11,"sex":17,"minAge":287,"maxAge":198,"enrollmentInfo":494,"targetDuration":496,"studyType":497,"phases":4,"briefSummary":498,"conditions":499,"keywords":502,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":515},"100228319","pediatric-pulmonary-hypertension-network-pphnet-informatics-registry-100228319","NCT02249923","Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry","PPHNet","Inclusion Criteria:\n\n* The subject's age of onset of pulmonary hypertension must be prior to age 18 years\n* The person providing consent must be able to read either Spanish or English.\n* The subject (and\u002For parent\u002Flegal guardian) must be able to provide informed consent\n\nExclusion Criteria:\n\n* Diagnosed with pulmonary hypertension after age 18\n* Refusal to sign informed consent",{"count":495,"type":22},2500,"5 Years","OBSERVATIONAL","Patients are being asked to be in this research study because medical researchers hope that by gathering information about a large number of children with pulmonary hypertension over time, their understanding of the disease process will increase and lead to better treatment. Investigators believe that pulmonary hypertension in children is different than pulmonary hypertension in adults and this study will help us understand those differences.",[500,501],"Pulmonary Vascular Disease","Pulmonary Arterial Hypertension",[503,504,505,506],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Vascular Disease (PVD)","Registry","Pediatric","2025-03-10",{"date":509,"type":33},"2025-03-13",{"date":511,"type":4},"2014-10",{"date":513,"type":22},"2031-12",{"name":39,"class":40},14,""]